Microbiology FDA 483 (Aurobindo/Eugia Pharma) : Procedures not established & followed to prevent microbiological contamination of sterile drug products
During aseptic filling operations, procedure HO-CQA-SOP-2*** “Clean Room Practices and Aseptic Behavior” and line specific intervention procedures were not followed: